Therapeutic administration of bone marrow-derived mesenchymal stromal cells reduces airway inflammation without up-regulating Tregs in experimental asthma.
J Z KitokoL L de CastroA P NascimentoS C AbreuF F CruzA C ArantesD G XistoM A MartinsM M MoralesP R M RoccoPriscilla C OlsenPublished in: Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology (2017)
MSCs therapeutically administered exert anti-inflammatory effects in the airway of HDM-challenged mice, but do not ameliorate lung function or remodelling. Although MSC pre-treatment can increase Treg cell numbers, it is highly unlikely that the MSCs will induce Treg cell expansion when lymphocytes are allergenically primed in an established lung inflammation.